Piperazine Heteroaryl Derivatives as Gpr38 Agonists
申请人:MacDonald Gregor James
公开号:US20080312209A1
公开(公告)日:2008-12-18
The invention provides compounds of formula (I) or pharmaceutically acceptable salts thereof,
wherein R
1
, R
2
, R
3
, R
4
, R
5
, R
6
, Z, X and B are as defined in the specification. The compounds are partial or full agonists at the GPR38 receptor. Pharmaceutical compositions comprising the compounds, methods of preparing the compounds, uses of the compounds and methods involving the compounds are also provided.
Disclosed is an aminopyrrolidine compound represented by the formula [I] or a pharmaceutically acceptable salt thereof. The compound or the salt is useful as a prophylactic/therapeutic agent for mode disorder such as depression, anxiety disorder, anorexia, cachexia, pain and drug dependence, whose action relies on the MC
4
receptor antagonistic effect.
Nitrogen-containing condensed cyclic compound having a pyrazolyl group as a substituent group and pharmaceutical composition thereof
申请人:Eisai R&D Management Co., Ltd.
公开号:EP2048142A2
公开(公告)日:2009-04-15
The present invention provides a compound having an excellent inhibitory action on activation of STAT6 and a pharmaceutical composition thereof. In particular, it provides a compound represented by the following formula (I), a salt thereof or a hydrate of them.
In the formula, the groups X,Y,Z,R1-R4 and n are defined as in claim 1.
本发明提供了一种对 STAT6 的活化具有极佳抑制作用的化合物及其药物组合物。特别是提供了由下式(I)代表的化合物、其盐或它们的水合物。
式中,基团 X、Y、Z、R1-R4 和 n 的定义如权利要求 1 所述。
NOVEL MALONIC ACID SULFONAMIDE DERIVATIVE AND PHARMACEUTICAL USE THEREOF
申请人:Mitsubishi Tanabe Pharma Corporation
公开号:EP2172450B9
公开(公告)日:2014-10-08
Adachi, Makoto; Sasakura, Kazuyuki; Sugasawa, Tsutomu, Chemical and pharmaceutical bulletin, 1985, vol. 33, # 5, p. 1826 - 1835